Božena Bollová
Country Manager for Slovakia at GeneTiCA Group and originally educated as a medical geneticist and molecular diagnostician. She has over seven years of experience supporting genomic and multiomic solutions aimed at rare disease diagnostics and cancer sample testing, including national projects such as the SARS-CoV-2 sequencing project.
The core of her work is coordinating a local team of specialists who focus on building partnerships and ensuring exceptional care for clients with whom GeneTiCA Group collaborates, mainly on projects involving next-generation sequencing. She supports these clients in their day-to-day operations and promotes their activities through seminars, workshops, and lectures.
Her high level of expertise and professional approach to the field and strategic tasks within GeneTiCA Group are evidenced by the outstanding results achieved in developing the Slovak team and in the growth and implementation of Slovak business projects.
The core of her work is coordinating a local team of specialists who focus on building partnerships and ensuring exceptional care for clients with whom GeneTiCA Group collaborates, mainly on projects involving next-generation sequencing. She supports these clients in their day-to-day operations and promotes their activities through seminars, workshops, and lectures.
Her high level of expertise and professional approach to the field and strategic tasks within GeneTiCA Group are evidenced by the outstanding results achieved in developing the Slovak team and in the growth and implementation of Slovak business projects.
Sign in to ITAPA Health&Care 2025
-
DISCUSSION “Whole genome sequencing: New trends and clinical added value“
-
Whole genome analysis (WGS) as a tool for personalized medicine - relevance for individualization of treatment approach and for the health system
Whole genome analysis is a modern tool of personalized medicine, providing a comprehensive view of the patient's genetic information. This procedure enables the detailed identification of genetic variants, which can be of fundamental importance for the early diagnosis and prognosis of diseases with the possibility of creating individual dispensaries and treatment plans. Benefits include more precise targeting of treatment, prediction of genetic disease risk, and better understanding of individual response to therapy, leading to optimization of healthcare and improved patient outcomes.